Brexit, Klaus Dugi, Lisa Anson, Mark Hicken, UK life sciences industrial strategy, UK pharma leaders survey 2017
0 Comment
breast cancer, cancer, cost-effectiveness, market access, NICE
0 Comment
Ruling could end funding for cancer drug in England.
haemophilia, Novo Nordisk, R&D, Roche, Shire
0 Comment
Roche hopes to take on Novo Nordisk and Shire.
fda, MS, multiple sclerosis, neurology, regulation, Roche
0 Comment
FDA to review new manufacturing data.
Alzheimer's, Genentech, neurology, Roche
0 Comment
Data suggest high dose used in phase 3 trial is most effective
Alvogen, flu, infectious diseases, influenza, Roche
0 Comment
Generic was developed with India’s Natco.
Cancer Drugs Fund, NICE
0 Comment
NICE says price cut made approval possible, despite continuing uncertainty about benefits
Bristol-Myers Squibb, cancer immunotherapy, Merck & Co, Roche
0 Comment
Initiative aims to find new immunotherapies.
cardiovascular, fda, filing, giant cell arteritis, Roche
0 Comment
Drug successful in late stage trial for giant cell arteritis
